ESMO
Investigators are trialing methods to boost sensitivity for certain cancers, and assessing measures of how tests may impact clinical care in certain screening subpopulations.
Observation alone resulted in positive outcomes for MRD-negative patients, whereas MRD-positive individuals may still need adjuvant chemotherapy.
Exact Sciences Blood-Based Colon Cancer Screening Data at ESMO Exceeds Expectations
Although the results were better than expected, the company cautioned that it expects lower performance in its prospective trial readout, planned for early next year.
Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.
Genomic Profiling Aids Patients With Cancers of Unknown Primary in Trial, Though Benefit is Limited
In the CUPISCO trial, molecularly guided treatment reduced the risk of progression or death by 28 percent compared to patients receiving chemotherapy.